Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models

Figure 1

Prophylactic effect of MT-1303 on the development of proteinuria in MRL/lpr mice. MT-1303 was administered to MRL/lpr mice for 18 weeks from 8 weeks of age. (a) Proteinuria was assessed once a week using Ames urinalysis strips and was scored on a scale of 0–4 based on urinary protein concentrations as described in Materials and Methods. Each symbol represents the score of 12 animals. Statistical significance was calculated using the Shirley-Williams test by comparison with the vehicle-treated control group (, ). (b, c) Kidney sections from vehicle- (b) or MT-1303 0.3 mg/kg- (c) treated mice were labeled with anti-mouse CD3 mAb. (d, e) The axillary lymph nodes (d) and spleen (e) were weighed on the day after final administration. Results are expressed as the of 8 mice. (f–h) The number of T cells (d), B cells (e), and abnormal T cells (CD3⁺B220⁺) (f) was measured by flow cytometry. Results are expressed as the of 4 mice. (d–h) Statistical differences were calculated using the Williams test by comparison with the control (, ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)